INTELLIA THERAPEUTICS INC (NTLA)
US45826J1051 - Common Stock
ChartMill assigns a Buy % Consensus number of 82% to NTLA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 72.38. This target is 248.63% above the current price.
NTLA was analyzed by 34 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about NTLA.
In the previous month the buy percentage consensus was at a similar level.
NTLA was analyzed by 34 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-23 | Wedbush | Reiterate | Neutral -> Neutral |
| 2024-02-23 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-02-23 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2024-02-15 | Wolfe Research | Initiate | Peer Perform |
| 2023-11-13 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-11-13 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-11-10 | BMO Capital | Maintains | Outperform -> Outperform |
| 2023-11-10 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-11-10 | Raymond James | Maintains | Outperform -> Outperform |
| 2023-11-10 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-09-13 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-29 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-07 | Chardan Capital | Reiterate | Buy -> Buy |
| 2023-08-07 | Barclays | Maintains | Overweight -> Overweight |
| 2023-08-07 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2023-08-04 | Barclays | Maintains | Overweight -> Overweight |
| 2023-08-04 | Citigroup | Maintains | Neutral -> Neutral |
| 2023-06-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2023-06-13 | Credit Suisse | Reiterate | Outperform -> Outperform |
| 2023-06-13 | B of A Securities | Maintains | Buy -> Buy |
| 2023-05-08 | Oppenheimer | Maintains | Outperform |
| 2023-05-08 | Morgan Stanley | Maintains | Overweight |
| 2023-05-08 | Citigroup | Maintains | Neutral |
| 2023-05-05 | BMO Capital | Maintains | Outperform |
| 2023-05-05 | Raymond James | Maintains | Outperform |
| 2023-04-13 | Canaccord Genuity | Initiate | Buy |
| 2023-03-31 | JP Morgan | Maintains | Overweight |
| 2023-03-21 | Bernstein | Initiate | Outperform |
| 2023-03-14 | BMO Capital | Upgrade | Market Perform -> Outperform |